PIK3CA and cervical squamous cell carcinoma: PIK3CA was mutated in 14% cervical squamous cell carcinoma patients in the study by Ojesa et al., Genomic profiling of advanced cervical cancer in the CLAP trial also showed a higher PFS in women with mutated PIK3CA receiving second line or later camrelizumab plus apatinib [24].